Novo Nordisk Suffers Setback - Analyst Blog

By
A A A

Novo Nordisk ( NVO ) recently faced a setback when the US Food and Drug Administration (FDA) declined to approve its diabetes candidates, Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart), on the basis of the submitted data.

The FDA issued a complete response letter (CRL) asking Novo Nordisk to conduct a dedicated cardiovascular outcomes study and provide additional cardiovascular data.

Moreover, the FDA said that it will not grant approval to these candidates until the company resolves the issues mentioned in a warning letter given by the FDA in Dec 2012. The warning letter specified violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at the company's Novo Alle, Bagsvaerd Denmark facility.

Meanwhile, we note that both Tresiba and Ryzodeg are approved in Japan, the EU and Mexico. In the EU, Novo Nordisk is planning to launch Tresiba first and Ryzodeg a year later. Tresiba and Ryzodeg will be available in Novo Nordisk's latest prefilled insulin pen named FlexTouch in Europe. Tresiba will initially be launched in the UK and Denmark in the first half of 2013 and in other European markets throughout 2013 and 2014.

Our Take

We are discouraged by the CRL issued by the FDA. Considering Novo Nordisk's statement that it will not be in a position to provide the required data in 2013, we expect a significant delay in the US approval of Tresiba and Ryzodeg. The US approval of Tresiba and Ryzodeg would have strengthened Novo Nordisk's diabetes franchise. We expect shares to react negatively to the news.  

Novo Nordisk currently carries a Zacks Rank #1 (Strong Buy). Other large-cap pharma companies like Sanofi ( SNY ), Bayer AG ( BAYRY ) and Eli Lilly and Company ( LLY ) also look well-positioned. All three companies are Zacks Rank #2 (Buy) stocks.



BAYER A G -ADR (BAYRY): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BAYRY , CRL , LLY , NVO , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          

Stocks

Referenced

Most Active by Volume

6,483,555
  • $96.16 ▼ 11.33%
3,389,006
  • $6.81 ▲ 0.59%
3,279,843
  • $17.61 ▼ 0.06%
2,953,933
  • $14.916 ▲ 4.97%
2,752,305
  • $7.209 ▲ 1.39%
2,510,423
  • $112.2199 ▲ 0.39%
2,334,542
  • $80.60 ▲ 0.90%
2,162,640
  • $7.82 ▼ 0.38%
As of 12/22/2014, 09:38 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com